Quotient Therapeutics

We transform somatic insights into potentially breakthrough medicines. Learn more at

[Quotient Therapeutics @QuotientTx]

Hear from our CEO, Rahul Kakkar, MD, in this past @FlagshipPioneer studio visit, as he explains what #SomaticGenomics is and how it can help to offer insights & enable the discovery of new medicines. Learn more: https://t.co/iGCFf0Ow51

[Quotient Therapeutics @QuotientTx]

Our #SomaticGenomics platform detects recurrent genetic mutations that cause or protect from disease, uncovering novel drug targets that inform the development of potentially breakthrough medicines. Learn more here: https://t.co/cnsMBnSsDv

[Quotient Therapeutics @QuotientTx]

This #DNADay, we recognize how DNA's discovery transformed our understanding of biology & disease. Through #SomaticGenomics we connect how changes in DNA contribute to disease & use those insights to develop new drugs. More here: https://t.co/iGCFf0Ow51

[Quotient Therapeutics @QuotientTx]

We're proud to share our work at the Mutations in Time and Space conference alongside the prestigious researchers in academia and industry, who are advancing the field of #SomaticGenomics.

[Quotient Therapeutics @QuotientTx]

Join us at the @eventsWCS' Mutations in Time & Space Conference in the UK or virtually as we share insights on the potential of our #SomaticGenomics platform to transform genetically-validated targets into potentially breakthrough medicines. More here: https://t.co/HFxkJnCncM

[Quotient Therapeutics @QuotientTx]

#ICYMI, our CEO, Rahul Kakkar, MD, spoke with Ryan Cross at @endpts to discuss our collaboration with Merck and how we’re applying our #SomaticGenomics platform to uncover novel drug targets for inflammatory bowel disease. Read more: https://t.co/u6OoWYj3ys

[Ryan Cross the Science Boss @RLCscienceboss]

Flagship Pioneering startup Quotient Therapeutics has struck its third pharma partnership, this time with Merck, to look for new drug targets based on the growing field of somatic genetics. More details on the approach in my latest for @endpts: https://t.co/oZkzqAL81a

[Quotient Therapeutics @QuotientTx]

We’re thrilled to announce our collaboration with @Merck to discover novel drug targets in IBD using our #SomaticGenomics platform. Together, we aim to uncover unique biological insights that drive the discovery of more effective tx for patients. Read more:https://t.co/dfpCMCNfef

[Quotient Therapeutics @QuotientTx]

In this @TheScientistLLC article, our CSO Peter Campbell discusses the potential of somatic genomics to understand disease biology and help to guide therapeutic development across a broad range of indications: https://t.co/8Sd3M2ubrv

[Quotient Therapeutics @QuotientTx]

We appreciate our Quotients today and every day as we work towards transforming #SomaticGenomics into potentially breakthrough medicines! #EmployeeAppreciationDay

[Quotient Therapeutics @QuotientTx]

Somatic mutations provide insights into disease, inspiring novel therapeutic strategies. Check out our @CellPressNews review of #SomaticGenomics & the field’s advancement towards genetically-validated drug target identification & clinical translation: https://t.co/w8u51zsqfp

[Quotient Therapeutics @QuotientTx]

#DYK, #SomaticMutations accumulate throughout our lives, beginning in utero? Using our #SomaticGenomics platform, we can study these mutations to uncover links between genes & diseases to develop potentially transformative medicines. Learn more: https://t.co/MiYycYvNGy

[Quotient Therapeutics @QuotientTx]

On International #WomenAndGirlsInScienceDay, we celebrate the women throughout our organization whose scientific rigor and leadership are key to advancing #SomaticGenomics and helping to push science forward every day. Learn more about our team: https://t.co/rYfnIuOjDP

[Quotient Therapeutics @QuotientTx]

Welcome Susan Keefe as our CFO! With 30 years of finance, accounting & operations experience building public & private life sciences cos, Susan brings strong strategic insight as we leverage #SomaticGenomics to build our internal & partnered portfolio: https://t.co/UcwkHEqKPd

[Quotient Therapeutics @QuotientTx]

Tune in to hear our CEO, Rahul Kakkar, M.D., in the @FlagshipPioneer studio at #JPM2026 discussing how #SomaticGenomics is reshaping how we understand disease & identify potential drug targets to develop medicines across a range of therapeutic areas: https://t.co/DqlhjQqPDn

[Quotient Therapeutics @QuotientTx]

The 2026 Annual Letter from @NoubarAfeyan is a timely reminder that scientific breakthroughs depend on protecting the conditions that make them possible. At #FlagshipFounded Quotient, we transform somatic genomics into breakthrough medicines, a #MiracleInTheMaking #JPM26

[Flagship Pioneering @FlagshipPioneer]

A future of progress depends on the choices we make today.

In his 2026 Annual Letter, Flagship’s Founder & CEO @NoubarAfeyan argues that at the very moment science is capable of delivering unprecedented breakthroughs, we are undermining the process that makes those miracles possible. The letter makes the case that progress is a choice, and by defending the scientific method, we can create a future defined by discovery, health, and prosperity.

 #MiraclesInTheMaking #JPM26

Full letter here: https://t.co/m80WHmlMHw

[Quotient Therapeutics @QuotientTx]

Our #SomaticGenomics platform lets us uncover #SomaticMutations that cause or protect against disease, revealing potential new drug targets. We can find these significant mutations with just 10-30 patients per study. Learn how: https://t.co/RBrP3rKhuf

[Quotient Therapeutics @QuotientTx]

#DYK the somatic genome comprises trillions of different genomes that exist in our cells due to #SomaticMutations? We study these mutations that occur throughout our lives to uncover genes causally implicated in the biology of various diseases. Learn more: https://t.co/BidSBqzb7L

[Quotient Therapeutics @QuotientTx]

We’re excited to announce our collaborations with @GSK under its framework collaboration with @FlagshipPioneer to discover and validate novel treatments in COPD, IPF and MASH using our somatic genomics technology. Read more: https://t.co/u6ie83r8et

[Quotient Therapeutics @QuotientTx]

Join us in welcoming Andy Bayliffe, PhD, as our Chief Development Officer. His 25+ years of drug discovery & development experience will be instrumental as we translate #SomaticGenomics into potentially breakthrough medicines for patients. Read more: https://t.co/XrCrwMBTXB

[Quotient Therapeutics @QuotientTx]

Our #SomaticGenomics platform follows a novel approach to uncovering links between genes and disease. This reveals a path to develop transformative therapeutics with intrinsically validated targets. Discover how our platform works: https://t.co/jZVBHcnI05